611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Pandemic Is Driving U.S. Surge in Cardiac Arrests Tied to OverdoseAmericans With Asthma Get First Updated Guidelines in Over a DecadePandemic Is Devastating Low-Income Black HouseholdsObesity Ups Women's Odds for Early Hip FractureFootball-Loving States Drop The Ball on Concussion: StudyCOVID Can Harm the Infant HeartCDC Director Warns of Dire Winter Ahead for COVID Hospitalizations, DeathsRelief for America's Unemployed Could Be Crucial for HealthMany Hospitalized COVID Patients Will Need Longer-Term Care at HomeCDC Shrinks COVID Quarantine Time, Advises Against Holiday TravelShould Cancer Survivors Be Prioritized for COVID Vaccine?Take Care of Your Mental Health During PandemicGay, Lesbian Adults Often Miss Out on Cholesterol MedsBritain Approves Emergency Use of Pfizer's COVID VaccineHealth Care Workers, Nursing Home Residents to Get First Vaccines: PanelNeed an IV or Stitches? Virtual Reality or Hypnosis Might Ease PainCOVID-19 Can Damage Lungs So Badly That 'Only Hope' is TransplantPandemic Could Be Golden Time for Narcissists: Study'Smell Training' Might Speed the Sense's Return After COVIDEye Injury Reported From Germ-Killing UV LampsCOVID Hospitalizations in U.S. Hit Record High'Repeat After Me' for Better Diabetes CareVentilators May Leave COVID Survivors With Windpipe InjuriesLockdown Loneliness Could Worsen Parkinson's SymptomsDiabetes, High Blood Pressure Raise Odds of COVID Harming BrainCOVID in Kids: The Most Telling SymptomsFauci Warns of Another Surge of COVID Cases After Thanksgiving TravelWood-Fired Cooking a Cause of Lung Illness in Developing WorldDelirium May Be Only Sign of Severe COVID in Elderly: StudySimple Move May Boost Spinal Fusion OutcomesCould the TB Vaccine Help Prevent COVID-19?When COVID Strikes Cancer Patients, Men Fare WorseMost Americans Over 50 Would Get COVID Vaccine: PollAnother Study Casts Doubt on 'Convalescent Plasma' as COVID-19 TreatmentCOVID Vaccine Rollout Could Begin Mid-December, Fauci SaysFauci: 'People Should Feel Confident' New COVID Vaccines Safe, EffectiveCould the Pill Reduce Asthma Attacks?Coronavirus Most Contagious Soon After InfectionPeople Should Know That COVID Vaccine Might Spur Transient Sickness: CDC ExpertsAnother Study Finds COVID Usually Mild in KidsBlacks, Hispanics Account for More Than Half of COVID Deaths: StudyCollege Kid Coming Home for Thanksgiving? Here's How to Keep Your Family SafeParents' Age Key to Whether Kids Get Vaccinated Against COVID, Study FindsVegan Diets Tied to Higher Bone Fracture RiskThird COVID Vaccine Shows Effectiveness; FDA Approves New TreatmentWhich Kids With COVID Will Get Very Sick?Add Kids to COVID Vaccine Trials, Pediatricians' Group SaysLosing Your Hair Because of Pandemic Stress?How Hospitals Can Cut Patients' FallsMany Young Americans Lonely, Depressed During Pandemic: Survey
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

An Antidepressant Might Help Prevent Severe COVID-19

HealthDay News
by Ernie Mundell
Updated: Nov 12th 2020

new article illustration

THURSDAY, Nov. 12, 2020 (HealthDay News) -- The antidepressant drug fluvoxamine -- best known by the brand name Luvox -- may help prevent serious illness in COVID-19 patients who aren't yet hospitalized, a new study finds.

The study included 152 patients infected with mild-to-moderate COVID-19. Of those, 80 took fluvoxamine and 72 took a placebo for 15 days.

By the end of that time, none of the patients who took the drug had seen their infection progress to serious illness, compared with six (8.3%) of the patients who took the placebo, according to researchers at Washington University School of Medicine in St. Louis.

"The patients who took fluvoxamine did not develop serious breathing difficulties or require hospitalization for problems with lung function," said first author Dr. Eric Lenze, professor of psychiatry.

"Most investigational treatments for COVID-19 have been aimed at the very sickest patients, but it's also important to find therapies that prevent patients from getting sick enough to require supplemental oxygen or to have to go to the hospital. Our study suggests fluvoxamine may help fill that niche," Lenze noted in a university news release.

Fluvoxamine -- widely used to treat depression, obsessive-compulsive disorder and social anxiety disorder -- is a type of drug called a selective serotonin-reuptake inhibitor (SSRI). This class of drugs also includes medicines such as Prozac, Zoloft and Celexa.

But unlike other SSRIs, fluvoxamine has a strong interaction with a protein called the sigma-1 receptor, which helps regulate the body's inflammatory response.

"There are several ways this drug might work to help COVID-19 patients, but we think it most likely may be interacting with the sigma-1 receptor to reduce the production of inflammatory molecules," explained study senior author Dr. Angela Reiersen, associate professor of psychiatry.

"Past research has demonstrated that fluvoxamine can reduce inflammation in animal models of sepsis, and it may be doing something similar in our patients," she said in the release.

By reducing inflammation, fluvoxamine may prevent a hyperactive immune response in COVID-19 patients. That, in turn, may decrease their risk of serious illness and death, Reiersen said.

"Our goal is to help patients who are initially well enough to be at home and to prevent them from getting sick enough to be hospitalized," Dr. Caline Mattar, assistant professor of medicine in the Division of Infectious Diseases, said in the release. "What we've seen so far suggests that fluvoxamine may be an important tool in achieving that goal."

Dr. Amesh Adalja is a senior scholar at the Johns Hopkins Center for Health Security in Baltimore. He wasn't involved in the study, but said the research is "notable not only because of its positive outcome -- we desperately need a medication that keeps COVID patients out of the hospital -- but also because of the manner in which it was conducted."

But Adalja stressed that a larger trial is needed "to see if the promising findings hold up."

The researchers said they plan to begin such a study in the next few weeks and it will include patients from across the United States.

The preliminary study was published online Nov. 12 in the Journal of the American Medical Association.

More information

For more on COVID-19, go to the U.S. Centers for Disease Control and Prevention.

SOURCES: Amesh Adalja, M.D., senior scholar, Johns Hopkins Center for Health Security, Baltimore; Washington University in St. Louis, news release, Nov. 12, 2020